1. Clinical & Scientific Overview
Dapagliflozin Propanediol Monohydrate (TIP-MED-000053, Reference Code [4.9]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • CDSCO Approved (T2DM, HFrEF/HFpEF, CKD).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.9], p. 49): Forxiga (AstraZeneca), Oxra (Sun Pharma), Udapa (Lupin), Gledepa, Dapamac (Macleods), Dapanorm (Alkem); In FDC with Metformin: Xigduo-XR, Oxramet; In FDC with Sitagliptin: Sidapvia / Oxra-S — Strengths & Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Oral Film-Coated Tablets: 5 mg, 10 mg
3. Mechanism of Action & Pharmacodynamics
Selectively and reversibly inhibits Sodium-Glucose Cotransporter-2 (SGLT2) in the S1 segment of the renal proximal convoluted tubule (PCT), which normally reabsorbs 90% of filtered glucose. Produces insulin-independent urinary glucose excretion (~70 g/day = ~280 kcal/day) and natriuresis, restoring tubuloglomerular feedback (afferent arteriolar constriction) and reducing intraglomerular hypertension.
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 Diabetes Mellitus (glycaemic control & CV event reduction)
- Heart Failure across the full ejection fraction spectrum (HFrEF & HFpEF — with or without diabetes)
- Chronic Kidney Disease (CKD) to slow eGFR decline and reduce ESKD/CV death
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults (T2DM, Heart Failure, or CKD): 10 mg orally once daily at any time of day.
Administration & Meal Timing: Oral; once daily with or without food.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.
For glycaemic lowering alone, efficacy declines when eGFR < 45 mL/min; however, for Heart Failure and CKD renoprotection, 10 mg/day may be initiated down to eGFR >= 25 mL/min and continued until dialysis.
In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.
7. Contraindications, Precautions & High-Risk Warnings
- Type 1 Diabetes Mellitus (high risk of euglycaemic DKA)
- Patients on dialysis
- Pregnancy and lactation
Key Clinical Precautions: In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.
8. Adverse Effects Profile
- Genital mycotic infections (vulvovaginal candidiasis, balanitis — 5%–8% due to glycosuria) and urinary tract infections
- Euglycaemic Diabetic Ketoacidosis (euDKA — blood glucose may be <250 mg/dL during surgery, fasting, or acute illness)
- Volume depletion, postural hypotension, and transient initial haemodynamic eGFR dip (3–5 mL/min)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Loop Diuretics (Furosemide): additive osmotic diuresis and volume depletion / orthostatic hypotension
- Insulin or Sulfonylureas (Glimepiride): reduce insulin/SU dose by 10–20% to prevent hypoglycaemia
- Lithium: SGLT2 inhibitors increase renal lithium clearance and may decrease serum lithium levels
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Hold Dapagliflozin at least 3 days before major scheduled surgery or during acute febrile dehydrating illness ('Sick-Day Rule') to prevent euglycaemic ketoacidosis.
- Maintain good perineal hygiene and adequate oral hydration to prevent genital fungal infections.
- Seek immediate medical care if nausea, vomiting, abdominal pain, or fruity breath develops even if blood glucose appears normal.
Storage, Stability & Dispensing Safeguards: Store below 30°C.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.23] Insulin Degludec (Ultra-Long Basal U-100 & Co-Formulation IDegAsp) — Ultra-Long-Acting Basal Insulin Analogue & Soluble Rapid+Basal Co
- [4.24] Glucagon & Oral / Intravenous Dextrose (Acute Severe Hypoglycaemia Protocol) — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
- [4.5]-CMP12 Glibenclamide (Glyburide) IP — Second/Third-Generation Sulfonylurea; Pancreatic Beta-Cell Insuli
- [4.6]-CMP13 Glibenclamide (Glyburide) IP — Second-Generation Sulfonylurea with Selective Pancreatic SUR1 Bin